MEDA Pharmaceuticals UK, suppliers of EpiPen® and EpiPen® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline), has assured the Department of Health that it has adequate product supply to cover all patients requiring replacement adrenaline auto-injectors (AAI) with immediate effect.
This confirmation is made in light of the voluntary product recall of Anapen® by Lincoln Medical which was announced on 23rd May 2012.
EpiPen® and EpiPen® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline) are used to treat signs and symptoms of a life-threatening allergic reaction (anaphylaxis), some of which include hives, redness of the skin, tightness in the throat, breathing problems and/or a decrease in blood pressure. A life-threatening allergic reaction (anaphylaxis) can be caused by triggers such as food, stinging and biting insects, medicines, latex, or even exercise.
Sufficient stock levels of EpiPen® and EpiPen® Jr Auto-Injectors (0.3 and 0.15 mg adrenaline) are available to cover all patients in the UK who require new AAIs.
Patient information and support materials are also available for patients requiring a switch in medication. For further stock and patient information enquiries please contact:
Tel: +44 (0)845 460 0000
Fax: +44 (0)845 460 0002